Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

NCT ID: NCT04955808

Last Updated: 2025-08-27

Basic Information

• Recruitment Status: SUSPENDED
• Total Enrollment: 2400 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-02-07
• Study Completion Date: 2026-12-31

Brief Summary

This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery. Studying samples collected during surgery may add to the understanding of cancer by looking for the genetic changes that cause early cancer onset in people of certain racial and ethnic groups.

Detailed Description

PRIMARY OBJECTIVE:

I. To acquire tissue and blood, and other biospecimens for research purposes during procedures for clinical care to accelerate our understanding of the molecular basis of early onset cancers occurring in racial and/or ethnic minority populations through the application of genome analysis technologies, including large- scale genome sequencing and clinical data analysis.

OUTLINE:

Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.

After completion of study, patients are followed for up at 6 and 12 months.

Conditions

Breast Carcinoma; Colon Carcinoma; Invasive Carcinoma; Kidney Carcinoma; Liver Carcinoma; Malignant Solid Neoplasm; Multiple Myeloma; Prostate Carcinoma

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Ancillary-correlative (biospecimen collection)

Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.

Biospecimen Collection

Intervention Type: PROCEDURE

Undergo collection of tissue and blood samples

Laboratory Biomarker Analysis

Intervention Type: OTHER

Correlative studies

Interventions

Biospecimen Collection

Undergo collection of tissue and blood samples

Intervention Type: PROCEDURE

Laboratory Biomarker Analysis

Correlative studies

Intervention Type: OTHER

Other Intervention Names

Biological Sample Collection; Biospecimen Collected; Specimen Collection

Eligibility Criteria

Inclusion Criteria

• Patients with either:

• Histologically confirmed invasive carcinoma or multiple myeloma OR
• Clinical diagnosis of carcinoma or multiple myeloma OR
• Suspected clinical diagnosis of multiple myeloma
• Patients with one of following tumor types and age ranges:

• Breast cancer diagnosis at ages 18-45
• Colon cancer diagnosis at ages 18-55
• Kidney cancer at diagnosis at ages 18-50 (American Indian or Alaska Native [AIAN] and non-Hispanic Whites [NHW] only)
• Liver cancer diagnosis at ages 18-55
• Prostate cancer diagnosis at ages 18-55
• Multiple myeloma diagnosis at ages 18-50
• Patients whose tumor specimen was collected or will be collected during one of the following routine procedures:

• Surgery to remove cancer OR
• Routine biopsy procedures performed to confirm a histologic diagnosis OR
• Routine biopsy procedure performed to obtain additional tumor material for routine prognostic or predictive biomarkers OR
• Routine procedure to place a vascular access device prior for systemic therapy
• Patients who have received no therapy for their cancer other than surgery, irrespective of stage
• Collection of specimens from living patients:

• Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol
• Collection of specimens from deceased patients:

• Banked tissue samples and/or banked biologic fluid specimens of deceased patients may be used as long as all samples or specimens are properly de- identified prior to submission
• Sites must use the Central Institutional Review Board for the National Cancer Institute (NCI CIRB).

Exclusion Criteria

• Patients who do not meet criteria for an early onset malignancy
• Prior systemic therapy or radiation therapy for their malignancy
• Tumor does not meet quality metrics
• Patient refused consent for use of tissue for research activities included in the Early Onset Malignancies Initiative
• A diagnosis of a synchronous invasive malignancy
• Patients with a history of invasive cancer or hematologic malignancy in preceding 5 years

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michelle Bennett

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute Division of Cancer Prevention

Locations

National Cancer Institute Division of Cancer Prevention

Rockville, Maryland, United States

Countries

United States

Other Identifiers

NCI-2017-01572

Identifier Type: REGISTRY

Identifier Source: secondary_id

DCP-002

Identifier Type: OTHER

Identifier Source: secondary_id

DCP-002

Identifier Type: OTHER

Identifier Source: secondary_id

DCP-002

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2017-01572

Identifier Type: -

Identifier Source: org_study_id